Such short-term omission of TB drugs before the next treatment cycle presumably would result in a low or residual level of MDR-TB infection, and such a setting would make it more readily to determine whether adjunctive ZOL/IL-2 or IL-2 regimen could exert better therapeutic effects than TB drugs alone. Here, IL2 is linked to tuberculosis.